Zevra therapeutics completes acquisition of acer therapeutics in its journey to become a leading rare disease company

Acquisition includes olpruva®, an fda-approved treatment for urea cycle disorders (ucds), which propels zevra into commercial stage, diversifying its revenue and providing scale settlement of acer's warrant obligations through direct transaction with a healthcare focused investment fund adds quality healthcare investor to zevra's shareholder base celebration, fla., nov. 20, 2023 (globe newswire) -- zevra therapeutics, inc. (nasdaqgs: zvra) (zevra or the company), a rare disease therapeutics company, today announced the completion of its acquisition of acer therapeutics inc. (acer) which marks a significant step forward in executing zevra's strategy to become a leader in developing and commercializing treatments for rare diseases and furthers the company's commitment to supporting patient communities with limited or no existing therapeutic options.
ZVRA Ratings Summary
ZVRA Quant Ranking